These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 720213)

  • 1. The role of drug disposition kinetics on cellular transport of the antineoplastic agent VM-26.
    Allen L
    Drug Metab Rev; 1978; 8(1):119-35. PubMed ID: 720213
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of uptake and binding of two epipodophyllotoxin glucopyranosides, 4'-demethyl epipodophyllotoxin thenylidene-beta-D-glucoside and 4'-demethyl epipodophyllotoxin ethylidene-beta-D-glucoside, in the L1210 leukemia cell.
    Allen LM
    Cancer Res; 1978 Aug; 38(8):2549-54. PubMed ID: 667850
    [No Abstract]   [Full Text] [Related]  

  • 3. Flux of teniposide (VM-26) across the plasma membrane of teniposide-resistant sublines of L1210 cells.
    Lee T; Roberts D
    Cancer Res; 1984 Jul; 44(7):2986-90. PubMed ID: 6722822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein-linked DNA strand breaks produced by etoposide and teniposide in mouse L1210 and human VA-13 and HT-29 cell lines: relationship to cytotoxicity.
    Kerrigan D; Pommier Y; Kohn KW
    NCI Monogr; 1987; (4):117-21. PubMed ID: 3041238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of 1-beta-D-arabinofuranosylcytosine transport and net accumulation by teniposide and etoposide in Ehrlich ascites cells and human leukemic blasts.
    White JC; Hines LH; Rathmell JP
    Cancer Res; 1985 Jul; 45(7):3070-5. PubMed ID: 4005845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical pharmacology of etoposide and teniposide.
    Clark PI; Slevin ML
    Clin Pharmacokinet; 1987 Apr; 12(4):223-52. PubMed ID: 3297462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teniposide (VM-26)- and etoposide (VP-16-213)-induced augmentation of methotrexate transport and polyglutamylation in Ehrlich ascites tumor cells in vitro.
    Yalowich JC; Fry DW; Goldman ID
    Cancer Res; 1982 Sep; 42(9):3648-53. PubMed ID: 6179605
    [No Abstract]   [Full Text] [Related]  

  • 8. Current development of podophyllotoxins.
    Canetta R; Hilgard P; Florentine S; Bedogni P; Lenaz L
    Cancer Chemother Pharmacol; 1982; 7(2-3):93-8. PubMed ID: 7044596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etoposide and teniposide. Bioanalysis, metabolism and clinical pharmacokinetics.
    Holthuis JJ
    Pharm Weekbl Sci; 1988 Jun; 10(3):101-16. PubMed ID: 3047665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical pharmacology of VM26 and VP16-213. A brief overview.
    Creaven PJ
    Cancer Chemother Pharmacol; 1982; 7(2-3):133-40. PubMed ID: 7044592
    [No Abstract]   [Full Text] [Related]  

  • 11. Kinetics of cytotoxicity of VM-26 and VP-16-213 on L1210 leukemia and hematopoietic stem cells.
    Vietti TJ; Valeriote FA; Kalish R; Coulter D
    Cancer Treat Rep; 1978 Sep; 62(9):1313-20. PubMed ID: 688275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expressions of resistance and cross-resistance in teniposide-resistant L1210 cells.
    Roberts D; Lee T; Parganas E; Wiggins L; Yalowich J; Ashmun R
    Cancer Chemother Pharmacol; 1987; 19(2):123-30. PubMed ID: 3568269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Verapamil-induced augmentation of etoposide accumulation in L1210 cells in vitro.
    Yalowich JC; Ross WE
    Cancer Res; 1985 Apr; 45(4):1651-6. PubMed ID: 3978633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotixin glucopyranoside derivatives.
    Allen LM; Creaven PJ
    Eur J Cancer (1965); 1975 Oct; 11(10):697-707. PubMed ID: 1204664
    [No Abstract]   [Full Text] [Related]  

  • 15. Selection and characterization of L1210 sublines resistant to teniposide (VM-26).
    Lee T; Roberts D
    Cancer Res; 1984 Jul; 44(7):2981-5. PubMed ID: 6722821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26).
    Danks MK; Yalowich JC; Beck WT
    Cancer Res; 1987 Mar; 47(5):1297-301. PubMed ID: 3469013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer.
    Evans WE; Sinkule JA; Crom WR; Dow L; Look AT; Rivera G
    Cancer Chemother Pharmacol; 1982; 7(2-3):147-50. PubMed ID: 7083455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of etoposide.
    Phillips NC; Lauper RD
    Clin Pharm; 1983; 2(2):112-9. PubMed ID: 6309469
    [No Abstract]   [Full Text] [Related]  

  • 19. Stereochemical characteristics of the folate-antifolate transport mechanism in L1210 Leukemia cells.
    Sirotnak FM; Donsbach RC
    Cancer Res; 1974 Feb; 34(2):371-7. PubMed ID: 4855750
    [No Abstract]   [Full Text] [Related]  

  • 20. Potentiation of etoposide-induced DNA damage by calcium antagonists in L1210 cells in vitro.
    Yalowich JC; Ross WE
    Cancer Res; 1984 Aug; 44(8):3360-5. PubMed ID: 6744270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.